Increased TB Risk in Psoriasis Patients on Etanercept Despite Isoniazid Prophylaxis: Study

Published On 2025-08-27 15:30 GMT   |   Update On 2025-08-27 15:30 GMT
Advertisement

Researchers have found in a new study that Psoriasis patients undergoing TNF inhibitor therapy remain at risk for tuberculosis infection even with isoniazid prophylaxis. Contrary to existing literature, etanercept-treated patients may face a higher TB risk compared to those receiving other TNF inhibitors.

Psoriasis is a chronic multi-systemic inflammatory disease. Anti-tumor necrosis factor (TNF) agents such as adalimumab, infliximab, etanercept are effectively used for treatment. The increased risk of infection, especially tuberculosis is a major concern for patients receiving TNF inhibitor therapy. The aim of this study was to evaluate frequency and risk of tuberculosis in psoriasis patients using anti-TNF therapy over a 16-year period. This study is based on data from the Turkish Psoriasis Registry (PSR-TR) and digital records of the Medical School of the Bezmialem Vakif University. Patients with tuberculosis were recorded and the details of the treatment they received were explored. Results: They detected 3 patients with pulmonary tuberculosis and 1 patient with tuberculosis peritonitis in spite of isoniazid chemoprophylaxis. The common feature of these patients was a history of etanercept treatment. They concluded that psoriasis patients receiving TNF inhibitor therapy are at risk of tuberculosis infection despite isoniazid prophylaxis and contrary to the literature it looks like those patients treated with etanercept may be at greater risk for tuberculosis than patients treated with other TNF inhibitor agents.

Reference:

Mert, Ömer, et al. "Frequency of Tuberculosis in Psoriasis Patients Using anti-TNF Therapy During 16 Years of Follow-up." Postepy Dermatologii I Alergologii, vol. 42, no. 3, 2025, pp. 276-282.


Keywords:

Increased, TB Risk, Psoriasis, Patients, Etanercept, Despite, Isoniazid, Prophylaxis, Study, Mert, Ömer,




Tags:    
Article Source : Postepy Dermatol Alergol - NCBI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News